Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?

Amphenol

Carpenter Technology

JPMorgan Chase & Co

On Holding AG

S&P 500 giant JPMorgan Chase has been hovering near a buy point since a Q3 earnings beat. Several stocks are in or near buy zones.

S&P 500 Giant Leads 5 Stocks Near Buy Points

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.

Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst

RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand

Lennox International

Tractor Supply

Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends.

My 3 Favorite Stocks to Buy Right Now

ResMed Inc. (NYSE:RMD ) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Low - JPMorgan Saul Hadassin - Barrenjoey Capital Anthony Petrone - Mizuho Daniel Hurren - MST Marquee Mike Matson - Needham & Company Brett Fishbin - KeyBanc Capital Markets Suraj Kalia - Oppenheimer Lyanne Harrison - Bank of America Andrew Paine - CLSA Operator Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.

ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript

The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago.

ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment.

ResMed beats quarterly profit estimates on strong demand for its sleep apnea devices

ResMed stock bounded higher late Thursday after the CPAP-maker shrugged off worries popular weight-loss drugs would hammer its top line.

ResMed Adds To Its Recent Sprint, Shrugging Off Worries Tied To Obesity Drugs

Leidos Hld

NetApp

Travelers

Trane Technologies plc

Leidos Holdings, NetApp, ResMed, Trane Technologies and Travelers could be compelling picks for investors looking for dividend stocks.

5 Top Dividend Stocks That Promise Substantial Growth

Besides Wall Street's top -and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why

RMD's robust mask business and efforts to boost its SaaS business are encouraging.

Is ResMed Stock a Smart Addition to Your Portfolio Right Now?

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Earnings Expected to Grow: Should You Buy?

Royal Philips

Investors with an interest in Medical - Products stocks have likely encountered both Royal Philips (PHG) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?

PHG or RMD: Which Is the Better Value Stock Right Now?

Agnico Eagle Mines

CRA International

NetApp (NTAP), Agnico Eagle (AEM), ResMed (RMD), Charles River (CRAI) and Leidos Holdings (LDOS) could be compelling picks in the final quarter of the year.

5 Dividend Growth Stocks to Buy in Q4

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024

Accenture Plc

Domino's Pizza

Elevance Health Inc

Global Payments

Intuit

Mastercard

MSCI

Nordson

NXP Semiconductors

Old Dominion Freight Line

Rollins

SPDR S&P 500 ETF Trust

Visa

Vanguard Dividend Appreciation ETF

Zoetis

The SPDR S&P 500 ETF Trust posted a gain of 2.10% in September as it continues marching on in 2024. The Top 15 dividend growth stocks for October 2024 offer an average dividend yield of 1.05% and appear to be about 20% undervalued based on dividend yield theory.

My Top 15 High Growth Dividend Stocks For October 2024

ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ResMed (RMD) Upgraded to Buy: What Does It Mean for the Stock?

Hubbell

Ferrari

Vertex, Inc.

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RACE, VERX, RMD and HUBB are some stocks that hold promise.

Scoop up These 4 GARP Stocks to Receive Handsome Returns

ResMed introduces digital and personalized solutions designed to improve sleep health.

RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions

NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed's plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, ResMed expects to help more than 500 million people worldwide achieve their full health potential in 2030.

ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns

ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir ™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling.

News for ResMed Stock (RMD)